M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Book ChapterDOI
The Princess Margaret Hospital Experience in the Management of Stage I and II Seminoma — 1981 to 1991
Mary Gospodarowicz,P.R. Warde,Tony Panzarella,C.N. Catton,Jeremy Sturgeon,Malcolm J. Moore,M. A. Jewett +6 more
TL;DR: With excellent results, minimal toxicity, and only a small risk of second cancers, there is reluctance to reassess the role of routine postoperative RT in stage I seminoma.
Journal ArticleDOI
Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
TL;DR: Fostriecin is an antitumor antibiotic with marked activity against ovarian, breast, and lung cancer cell lines in the human tumor clonogenic assay and in vitro it has been shown to inhibit macromolecular synthesis, interact with the reduced folate carrier system, and inhibit topoisomerase II.
Journal ArticleDOI
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.
Timothy J. Hobday,Rui Qin,Diane Lauren Reidy,Malcolm J. Moore,Jonathan R. Strosberg,Andreas Kaubisch,Manisha H. Shah,Hedy L. Kindler,Heinz-Josef Lenz,Helen X. Chen,Charles Erlichman +10 more
TL;DR: A phase II trial of the mTOR inhibitor TEM and the VEGF-A monoclonal antibody BEV in patients with well or moderately differentiated PNET and progressive disease by RECIST within 7 months of study entry, reporting improved progression-free survival and co-primary endpoints RR and 6-month PFS.
Journal ArticleDOI
The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.
Michael M Vickers,Chris Karapetis,Dongsheng Tu,Christopher J. O'Callaghan,Timothy J. Price,Niall C. Tebbutt,G. Van Hazel,Jeremy Shapiro,Nick Pavlakis,Peter Gibbs,J. Blondal,U. J. Yu Min Lee,J. M. Meharchand,Ronald Burkes,S. H. Rubin,John Simes,John Zalcberg,Malcolm J. Moore,Liting Zhu,Derek J. Jonker +19 more
TL;DR: In contrast to prior reports, grade ≥1 (and ≥20% reduction from baseline) CET-induced hMg was associated with poor OS, even after adjustment for grade of rash, in patients with pretreated ACC.
Journal ArticleDOI
Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS).
Mohammad Abu Zaid,Howard D. Sesso,Chunkit Fung,Darren R. Feldman,Robert J. Hamilton,David J. Vaughn,Clair J. Beard,Malcolm J. Moore,Deepak M. Sahasrabudhe,Eileen Johnson,Sophie D. Fosså,Lawrence H. Einhorn,Lois B. Travis +12 more
TL;DR: This study examined the number and range of co-morbidities following CHEM in uniformly treated patients with tinnitus, hearing loss, peripheral neuropathy, balance/vertigo, renal disease, hypertension (HTN), Raynaud’s syndrome, diabetes (DM), thyroid disease, hypogonadism, erectile dysfunction (ED), anxiety/depression, pain, and others.